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Abstract
Background: Generation of extended- spectrum β- lactamases is one of the major mechanisms by which clinical
Klebsiella pneumoniae develop resistance to antibiotics. Combined antibiotics prove to be a relatively effective
method of controlling such resistant strains. Some of Chinese herbal active ingredients are known to have synergistic
antibacterial effects. This study is aimed to investigate synergistic effects of Chinese herbal active ingredients with
cefotaxime on the extended- spectrum β- lactamase positive strains of Klebsiella pneumoniae, and to analyze
mechanism of synergistic action, providing experimental evidence for clinical application of antimicrobial drugs.
Results: For total sixteen strains including fifteen strains of cefotaxime resistant K. pneumoniae and one extended-
spectrum β- lactamase positive standard strain, the synergy rates of cefotaxime with baicalein, matrine, and clavulanic
acid were 56.3 %, 0 %, and 100 %, respectively. The fractional inhibitory concentration index of combined baicalein and
cefotaxime was correlated with the percentage decrease of cefotaxime MIC of all the strains (r = −0.78, p <0.01). In the
group of synergy baicalein and cefotaxime, the transcribed mRNA level of CTX-M-1 after treatment of baicalein was
decreased significantly (p <0.05). Moreover, the CTX-M-1 mRNA expression percentage inhibition (100 %, 5/5) was
significantly higher than non- synergy group (25 %, 1/4) (p <0.05).
Conclusions: Our study demonstrated that baicalein exhibited synergistic activity when combined with cefotaxime
against some of extended- spectrum β- lactamases positive K. pneumoniae strains by inhibiting CTX-M-1 mRNA
expression. However, no direct bactericidal or bacteriostatic activity was involved in the synergistic action. Baicalein
seems to be a promising novel effective synergistic antimicrobial agent.
Keywords: Baicalein, Extended- spectrum β- lactamases, Klebsiella pneumoniae, Synergistic antibacterial action,
CTX-M-1 gene
Background
Extended- spectrum β- lactamases (ESBLs) have the ability
of hydrolyzing a variety of antibiotics, such as penicillin,
cephalosporins, and monobactams. It is the main
mechanism for the formation of various kinds of bac-
terial resistance. ESBL can be suppressed by commonly
used β- lactamase inhibitors, such as clavulanic acid by
binding to and inhibiting the activity of ESBL when
combined with antibiotics. Combined antibiotics prove
to be a relatively effective method of controlling such
resistant strains [1]. However, in recent years, the emer-
gence of resistant strains of β- lactamase inhibitors re-
sults in failure of interactive antibiotic treatment.
Seeking for new and effective synergistic antimicrobial
agents to overcome bacterial resistance are urgently
needed.
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Chinese medical herbs have been a rich resource for the
discoveries of alternative synergistic antimicrobial agents.
Several studies show that certain active ingredients of
Chinese herbs have synergistic inhibitory effects on bac-
teria with antibiotics, such as baicalein and matrine [2, 3].
Baicalein is a type of flavonoids from the roots of Scutel-
laria baicalensis and Scutellaria lateriflora, which is one
of the most commonly used Chinese herbs in China for
the treatment of bacterial infections [4]. Synergies of bai-
calein were identified in combination with tetracycline or
β-lactams against two methicillin-resistant Staphylococcus
aureus (MRSA) clinical isolates OM481 and OM584 [2].
Baicalein was also reported to have synergy with gentami-
cin against vancomycin-resistant Enterococcus [5]. Chan et
al. reported synergistic effects of baicalein with ciprofloxa-
cin against NorA over-expressed methicillin-resistant
MRSA [6].
Klebsiella pneumoniae (K. pneumoniae, KP) is a type
of Gram-negative bacteria that can cause different types
of infections, including pneumonia, bloodstream infections,
wound or surgical site infections, and meningitis (http://
www.cdc.gov/HAI/organisms/klebsiella/klebsiella.html). In-
creasingly, Klebsiella bacteria have developed antimicrobial
resistance with a higher detection rate of ESBL [7, 8]. With
a wide range of therapeutic benefits, the synergy of baica-
lein with other antibiotics against K. pneumoniae may be
identified. The aim of the present study was to investigate
antibacterial effects of baicalein in association with cef-
otaxime against ESBL positive K. pneumoniae compared
with another candidate Chinese herbal ingredient named
matrine, which is a kind of alkaloids containing lactam
ring structure from the Sophora genus. Moreover, possible
mechanisms by which baicalein interacts with cefotaxime
against K. pneumoniae were studied.
Methods
Reagents and Chinese herbal active compounds
Cefotaxime was purchased from Harbin Pharmaceutical
Group Co., LTD General Pharm Factory. Clavulanic acid
and baicalein were purchased from Sigma. Matrine was
purchased from National Institutes for Food and Drug
Control. Cefotaxime and matrine were dissolved in ster-
ile water. Baicalein was dissolved in dimethyl sulfoxide
(DMSO) whose final concentration was less than 1 % ac-
cording to the Clinical and Laboratory Standards Institute
(CLSI, USA). Clavulanic acid was dissolved in Phosphate
buffer (pH 6.0, 0.1 mol/L).
Collection of ESBL positive K. pneumoniae clinical isolates
and identification
The clinical isolates of ESBL positive K. pneumoniae were
collected in the Affiliated Hospital of Harbin Medical
University. They were identified using an API20E system
(bioM´erieux, Marcy I’Etoile, France) with conventional
biochemical methods. Finally 15 strains were randomly se-
lected for this experiment. Quality control strain Escheri-
chia coli ATCC 25922 and K. pneumoniae ATCC 700603
were kept in our laboratory.
Measurement of β- Lactamase activity of clinical isolates
of K. pneumoniae
β- Lactamase activity was assessed by nitrocefin test.
The ESBL- producing strains were validated according
to CLSI recommended methodology [9].
Determination of the minimum inhibitory concentration
(MIC)
MIC was defined as the lowest concentration of a drug
that prevents visible growth of a bacterium. All drugs were
diluted in Mueller-Hinton Broth (MHB). Each test well
contained bacteria in a final concentration of 5 ×
105 CFU/mL. After 17 h’ incubation at 37 °C, they were
checked for growth. Escherichia coli ATCC 25922 was
used as sensitivity control strain. All experiments were re-
peated three times.
Since baicalein is colorful, we determined to use com-
bined visual observation and spectrophotometer method
to identify the MIC of drugs. The OD value of each well
was read at 630 nm wavelength. The growth of bacteria
after treatment was calculated using formula: bacterial
growth rate = 100 % ×ODdrug- containing well/ODdrug- free well,
where OD value is obtained by subtracting the back-
ground OD value from the measured value in each well.
MIC was determined as the lowest concentration of the
drug on the inhibition rate of more than 90 % [6].
Synergy testing of Chinese herbal active compounds with
antibiotic using checkerboard dilution method
To investigate if baicalein and matrine have synergy with
cefotaxime against K. pneumoniae in vitro, checkerboard
dilution method was used [10]. Two drugs were diluted
in MHB into 8 gradient concentrations, i.e., 1/32 ×
MIC- 4 ×MIC, each longitudinal column of wells hav-
ing the same concentration of drug A, and each hori-
zontal row of wells having the same concentration of
drug B. The total volume of each well was 200 μL, in-
cluding 50 μL of drug A, 50 μL of drug B, and 100 μL
of bacterial suspension with a final bacterial concentra-
tion of 5 × 105 CFU/mL. In addition, single drug MIC
control wells, drug- free control wells, bacteria- free
control wells were established. Escherichia coli ATCC
25922 was used as sensitivity control strain. After incu-
bation at 37 °C for 17 h, the MIC value was read. Each
experiment was repeated three times. Synergy was deter-
mined by calculating the fractional inhibitory concentra-
tions index (FICI) using formula: FICI =MIC drug A
combined with/MIC drug A used alone +MIC drug B in combination
with/MIC drug B alone, where MIC drug A combined with denotes
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the MIC of drug A when used in combination, MIC drug A
used alone denotes the MIC of drug A when used alone,
MIC drug B in combination with means the MIC of drug B
when used in combination, and MIC drug B alone means the
MIC of drug B when used alone. Based on the FICI, the
results of the interactive effects were as follows: FICI≤0.5
means synergy, 0.5 <FICI≤0.75 means partial synergy,
0.76 <FICI≤1 means additive, 1 <FICI≤4 denotes indiffer-
ent, FICI> 4 indicates antagonistic [10]. In this study, the
synergy and the partial synergy were defined as synergy
relationship, while the additive, the indifferent and the an-
tagonistic were classified as non- synergy relationship, in
order to facilitate statistical analysis.
Detection of blaSHV, blaTEM, blaCTX-M-1, blaCTX-M-9 in clinical
isolates of K. pneumoniae
Genomic DNA as templates were prepared using boiling
pyrolysis method from clinical isolates of K. pneumoniae.
Specific PCR primers for genes blaSHV, blaTEM, blaCTX-M-1
and blaCTX-M-9 were determined in our previous study
[9, 11] listed in Table 1. PCR reaction conditions were
as follows: initial denaturation at 94 °C for 3 min,
followed by 25 cycles of denaturation at 94 °C for 30 s,
annealing for 30 s, and extension at 72 °C for 1 min,
then extension at 72 °C for 5 min. PCR product was
subjected to 1.2 % agarose gel electrophoresis, followed
by staining and examination.
Measurement of mRNA transcriptional expression levels
of blaTEM, blaCTX-M-1 and blaCTX-M-9 in the clinical isolates
of K. pneumoniae by reverse transcription (RT)-PCR
Total RNAs were isolated using TRIzol (Invitrogen,
Carlsbad, CA) method [9] from the bacteria. Random
primers (Takara) and Moloney murine leukaemia virus
reverse transcriptase (Promega) were used for RT, then
PCR was run using bacterial 16SrRNA as internal con-
trol, primers 5' -GGA CGG GTG AGT AAT GTC- 3
'and 5' -ACA CCT GGA ATT CTA CCC- 3 '. The ex-
pected amplified fragment was 578 bp, and the annealing
temperature was 56 °C. The primers and other reaction
conditions were the same as in Table 1. The product was
subjected to 1.2 % agarose gel electrophoresis. Then it was
stained and analysis of target band was performed using
grayscale analysis software Image J to generate relative
mRNA expression levels, The intensity was expressed as a
value relative to that of the 16SrRNA [12]. Each experi-
ment was repeated three times.
Counting of viable K. pneumoniae after treatment of
baicalein and measurement of transcriptional expression
of ESBL genes
To further understand the mechanisms by which baicalein
works in combination with cefotaxime against these clin-
ical isolates, we repeated the experiments with baicalein
alone at the lowest inhibitory concentration determined
during combination. Baicalein was added to the same
MHB with clinical strains at the lowest inhibitory concen-
tration determined when used in combination with cefo-
taxime. Bacterial concentration was 5 × 105 CFU/mL.
Blank control without baicalein was used for comparison.
After 17 h’ incubation at 37 °C, 50 μL of bacterial suspen-
sion was taken for serial 10-fold dilution. Approximately
10 μL of bacterial inoculum was inoculated on the
medium of agar plates for 17 h at 37 °C. Then viable bac-
terial counting was conducted. All tests were performed
in triplicate. The results were expressed as mean ± stand-
ard deviation using CFU/mL as unit. At the same time,
the mixed baicalein and bacterial inoculum was used for
total RNA isolation. RT- PCR performed in the same ways
as above. Each experiment was repeated three times.
Statistical analysis
Statistical analysis was performed using the Fisher’s
Exact Test, Student’s t test and correlation analysis with
SPSS 16.0 software. p <0.05 was considered statistically
significant.
Results
Interactive antibacterial effects of Chinese herbal active
ingredients and clavulanic acid with cefotaxime
To investigate if baicalein can interact with cefotaxime
in the control of K. pneumoniae, synergy testing was
Table 1 Primers for ESBLs detection by PCR
Primer Sequence(5’→ 3’) Nuleotide position Tm Genbank accession No. Size
SHV-F TCTCCCTGTTAGCCACCCTG 224-243 59 °C AF124984 593 bp
SHV-R CCACTGCAGCAGCTGCCGTT 797-816
TEM-F GTATCCGCTCATGAGACAATA 154-174 56 °C AB194682 717 bp
TEM-R AGAAGTGGTCCTGCAACTTT 851-870
CTX-M1-F CGCTTTGCGATGTGCAG 264-280 56 °C X92506 551 bp
CTX-M1-R ACCGCGATATCGTTGGT 798-814
CTX-M9-F ATGGTGACAAAGAGAGTGCA 132-151 56 °C AJ416345 868 bp
CTX-M9-R CCCTTCGGCGATGATTCTC 983-1000
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conducted on baicalein, matrine, and clavulanic acid
with cefotaxime using checkerboard dilution method.
The results (Table 2, Fig. 1a) showed that when com-
bined with cefotaxime, baicalein exhibited synergistic ef-
fects on some antibiotic- resistant ESBL- positive strains
of K. pneumoniae (56.3 %). But no synergy was observed
with matrine (0 %). On the contrast, the positive control
drug clavulanate acid showed 100 % synergistic. These
findings indicated that baicalein may have moderate
synergy with cefotaxime against K. pneumoniae in vitro. A
further correlation analysis demonstrated that the FICI of
baicalein and cefotaxime was negatively correlated with
the percentage of cefotaxime MIC decrease (r = -0.78,
p <0.01) (Fig. 1b).
Number of K. pneumoniae after baicalein treatment in
interactive concentrations
To further investigate if baicalein can directly inhibit
bacterial growth independently, the strains of clinical
ESBL positive K. pneumoniae in synergy group was
treated alone with baicalein at the same lowest inhibitory
concentration determined when used in combination
with cefotaxime. Each strain was treated both by baica-
lein alone and no baicalein. After incubation, counting
of viable bacteria was conducted. The viable bacterial
counting revealed that there was no significant differ-
ence (P > 0.05) in the number of viable bacterial colonies
between baicalein treated and blank control groups
(Fig. 2). This finding suggests that baicalein may not
have direct bactericidal action when used in combination
with cefotaxime against K. pneumoniae.
Distribution of ESBL genes and their mRNA expression
changes in K. pneumoniae treated with interactive
concentration baicalein
To investigate if the synergy of baicalein with cefotaxime
is associated the distribution of resistant genes in the clinical
strains of K. pneumoniae, the percentages of ESBL resistant
genes, including blaSHV、blaTEM、blaCTX-M-1、blaCTX-M-9
were compared between synergy group and non-synergy
group (Fig. 3). The results showed that there were 2 strains
with blaSHV in the synergy group; 12 strains with blaTEM
both in synergy group and non-synergy group (each n = 6).
The percentage of blaTEM was 75 % in the synergy group
and 85.7 % in non-synergy group. There were 9 strains with
blaCTX-M-1, including 5 strains in synergy group with 62.5 %
and 4 strains in non-synergy group with 57.1 %. There were
9 strains with blaCTX-M-9, including 5 strains in the synergy
group with 62.5 % and 4 strains in the non-synergy group
with 57.1 %. Comparison analysis showed that there was no
significant difference in the distribution of the four common
ESBL resistance genes (P > 0.05), suggesting that the synergy
of baicalein and cefotaxime may not be associated with the
distribution of these resistance genes.
To further investigate if baicalein interacts with cefo-
taxime through regulation of gene expression, 15 clinical
strains of ESBL positive K. pneumoniae were treated
with baicalein alone at the same MIC determined during







bBai cMat dCla Cefotaxime bBai cefotaxime cMat cefotaxime dCla cefotaxime
28 >256 >256 16 128 128 128 1.5 2 128 1.008 0.5 4 0.063*
30 >256 >256 8 128 64 64 0.75* 2 128 1.008 0.5 4 0.094*
58 >256 >256 32 256 128 128 1 2 256 1.008 0.5 8 0.047*
64 >256 >256 32 256 1 256 1.004 2 256 1.008 0.5 8 0.047*
80 >256 >256 32 512 64 256 0.75* 2 1024 2.008 0.5 16 0.047*
90 >256 >256 8 1024 128 1024 1.5 2 1024 1.008 0.5 32 0.094*
102 >256 >256 16 128 32 64 0.63* 2 128 1.008 0.5 4 0.063*
116 >256 >256 8 128 128 64 1 2 128 1.008 0.5 4 0.094*
171 >256 >256 16 128 128 64 1 2 128 1.008 0.5 4 0.063*
179 >256 >256 8 1024 64 256 0.5* 2 1024 1.008 0.5 32 0.094*
210 >256 >256 8 256 128 64 0.75* 2 256 1.008 0.5 8 0.094*
219 >256 >256 8 1024 1 1024 1.004 2 1024 1.008 0.5 32 0.094*
796 >256 >256 8 256 32 64 0.38* 2 256 1.008 0.5 8 0.094*
826 >256 >256 8 1024 128 256 0.75* 2 1024 1.008 0.5 32 0.094*
863 >256 >256 8 256 128 64 0.75* 2 256 1.008 0.5 8 0.094*
700603 >256 >256 8 4 4 2 0.52* 2 4 1.010 1 1 0.38*
*FICI ≤0.75 means synergy group including both synergy and partial synergy
aFICI≤0.5 synergy, 0.5 <FICI≤0.75 partial synergy, 0.76 <FICI≤1 additive, 1 <FICI≤4 indifferent, FICI> 4 antagonistic
bBai:baicalein; cMat:matrine; dCla:clavulanate acid
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synergy testing. After incubation, the effect of baicalein
on mRNA expression of these resistance genes was
studied using RT-PCR. The results showed that baicalein
significantly inhibited the expression of CTX-M-1 in
strains KP30, KP80, KP179, KP796, KP826, KP219
(P < 0.05) (Figs. 4, 5, and 6, Table 3). Moreover, the
CTX-M-1 mRNA expression percentage inhibition
(100 %, 5/5) was significantly higher than non- synergy
group (25 %, 1/4) (p <0.05), implying that synergy of
baicalein with cefotaxime may be associated with the
inhibition of CTX-M-1 mRNA expression.
Discussion
ESBLs play a major role in the development of antibiotic
resistance in Gram- negative bacteria. It can damage the
structure of β- lactam antibiotics, preventing their bind-
ing to penicillin binding protein. ESBL encoding genes
consist mainly of SHV, TEM, CTX-M, OXA, GES, PER,
and VEB [13]. The most common ESBL genes in K.
pneumoniae are SHV, TEM, and CTX-M [14], among
them CTX-M being the dominant gene for β- lactam
antibiotic resistance in ESBL positive K. pneumoniae
[15, 16]. Based on their amino acid changes, CTX-M
type of β- lactamases are mainly divided into five groups:
CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9, and CTX-
M-25. CTX-M-14 (belonging to CTX-M-9 group) and
CTX-M-15 (belonging to CTX-M-1 group) are two
major genes in mainland China [17]. For example, a re-
cent study identified 88 % of CTX-M-1 ESBLs among 92
CTX-M ESBL-positive strains of K. pneumoniae isolated
from respiratory tract samples [18]. Therefore, the four
Fig. 1 Synergy comparison and correlation analysis of FICI with cefotaxime MIC value decrease. (The synergy testing of baicalein, matrine, and
clavulanic acid with cefotaxime in bacterial inhibition showed that different synergy rates, which is the percentage of synergistic strains among
the total strains studied, were observed with cefotaxime (a). Correlation between the FICI of baicalein with cefotaxime and baicalein-induced
cefotaxime MIC decrease percentage was analyzed using SPSS (b). X-axis denotes the FICI of baicalein with cefotaxime, Y-axis means cefotaxime MIC
decrease percentage)
Fig. 2 Effects of interactive concentration baicalein on the growth
of K. pneumoniae. (For each strain, Bai (+) and Bai (−) were compared.
Bai (+) denotes baicalein treated strain; Bai (−) denotes blank control
strain. Each experiment was conducted in triplicate. X-axis denotes
bacterial strain ID; Y-axis means log10 value of bacterial numbers)
Fig. 3 Comparison of ESBL gene percentage among different groups.
(The percentage of four common ESBL resistance genes in the synergy
group and non-synergy group was compared using Fisher’s Exact Test
with SPSS software, p <0.05 was considered statistically significant.
Black columns represent the percentage of the target genes in the
synergy group, while white columns denote the percentage of the
target genes in the non-synergy group)
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Fig. 4 Effect of baicalein on the mRNA expression of TEM. (Bai (+) denotes baicalein treated strain in black columns; Bai (−) means blank control
strain in white columns. Each strain was divided into baicalein treated and blank control subgroups for comparison of the effect of baicalein on
mRNA expression. RT-PCR products were analyzed using Image J software. The mRNA level was expressed as the gray value of target gene relative to
that of the 16SrRNA. Each experiment was done in triplicate. The mRNA value was expressed as mean ± standard deviation. The difference
was analyzed using Student’s t test. *p < 0.05 meaning statistically significant)
Fig. 5 Effect of baicalein on the mRNA expression of CTX-M-1. (same as Fig. 4 in explanation)
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commonly seen genes in mainland China, including
SHV, TEM, CTX-M-1, and CTX-M-9, were selected as
target resistance genes in this study.
Clavulanic acid as a commonly used β- lactamase in-
hibitor in practice can competitively bind with β- lacta-
mases, forming acyl - enzyme complex to inhibit their
activities, thereby cooperating with antibiotics. But cla-
vulanic acid resistant clinical strains [19] have occurred.
Chinese herbal active ingredients, including mainly
flavonoids and alkaloids, have antibacterial activity and
less toxicity. Baicalein is isolated from Chinese herb as
flavonoid, which has synergistic antimicrobial effects
[5, 6, 20]. This study demonstrated that baicalein may
cooperate with cefotaxime to inhibit ESBL positive K.
pneumoniae. But baicalein can only partially inhibit re-
sistant strains of ESBL positive bacteria through sup-
pressing the mRNA expression of CTX-M-1. Meanwhile,
there was no remarkable change in the number of viable
bacteria when treated alone with baicalein, implying that
baicalein exhibits synergistic antibacterial effect through
non- bacteriostatic nor bactericidal mechanisms.
Our previous studies showed that there was difference
in the mRNA expression level of ESBL resistance gene
SHV in clinical strains of K. pneumoniae. The variation
was also associated with antibiotic resistance in bacteria.
Therefore we proposed a new strategy for managing
bacterial resistance through regulating the expression of
ESBL resistance genes [9]. However, there is no report on
whether some medicine may have antibacterial effects by
inhibiting the expression of resistant genes.
In this study, we first validated the synergy of baicalein
with cefotaxime. Then we ruled out the possibility of
bacteriostatic or bactericidal activities of synergistic
baicalein. The effects of difference in resistance gene
distribution on antibiotic resistance in bacterial strains
were also investigated. This is the first report on inter-
action mechanism by which baicalein works with antibi-
otics through regulating the expression of resistance genes.
Relevant studies and our work showed that bacterial
CTX-M gene is associated with cefotaxime resistance
[11, 21]. CTX-M gene transfer experiments also confirmed
that the CTX-M gene enables the bacteria to cefotaxime
Fig. 6 Effect of baicalein on the mRNA expression of CTX-M-9. (same as Fig. 4 in explanation)
Table 3 Relationship of combined baicalein with cefotaxime and the mRNA level of resistant genes
Group Synergy Non- synergy P value
Inhibition(%) Non- inhibition (%) Inhibition(%) Non- inhibition(%)
TEM mRNA 100(6/6) 0(0/6) 33.3(2/6) 66.7(4/6) 0.061
CTX-M-1 mRNA 100(5/5) 0(0/5) 25(1/4) 75(3/4) 0.048*
CTX-M-9 mRNA 100(5/5) 0(0/5) 75(3/4) 25(1/4) 0.444
Based on the information in the Figs. 4, 5 and 6, the percentage of inhibited strains for each gene in synergy group and non-synergy group was compared using
Fisher’s Exact Test with SPSS
*p <0.05 statistically significant
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resistance [22]. In this study, down regulation of CTX-M-1
gene expression was found to be associated with cefotax-
ime MIC decrease. However, genes TEM and CTX-M-9
were not determinants of K. pneumoniae resistance to cef-
otaxime. It was shown that the gene expression of TEM,
CTX-M-1, and CTX-M-9 was inhibited by baicalein in a
clinical strain of bacteria, K. pneumoniae 219. But no syn-
ergy and cefotaxime MIC value decrease were observed.
The possible reasons for this may be that this strain has
various types of β- lactamase genes or other resistance
mechanisms, which cover up the inhibitory effect of baica-
lein on the expression of certain ESBL genes.
In summary, the present study investigated the inter-
active effect of baicalein on bacterial drug resistance at
molecular level. Our findings may pave a new way for
further searching for synergistic antimicrobial drugs.
More work should be done to confirm how baicalein
down- regulates gene expression and why it only works
in some strains.
Conclusions
Our results demonstrated that baicalein exhibited syner-
gistic activity when combined with cefotaxime against
some of ESBL positive K. pneumoniae strains by inhibit-
ing CTX-M-1 mRNA expression. However, no direct
bactericidal or bacteriostatic activity was involved in the
synergistic action. Baicalein seems to be a promising
novel effective synergistic antimicrobial agent.
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